Immunicum intends to use its proprietary platform technologies, enabling development of a broad spectrum of different immunotherapies, to form strategic alliances with suitable partners. The company aims to successfully complete clinical phase II trials and subsequently seek to partner with established actors in the pharmaceutical industry with which to complete clinical phase III trials and market the vaccine.

Upon completion of the clinical phase I/II trials in RCC and in melanoma (together with Cancer Vaccine Institute), Immunicum welcomes prospective partners to take part in planning the upcoming clinical phase II trials.